Global Dengue Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
878.54 Million
USD
2,121.43 Million
2023
2031
 예측 기간 |
2024 –2031 |
 시장 규모(기준 연도) |
USD 878.54 Million |
 시장 규모(예측 연도) |
USD 2,121.43 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
글로벌 뎅기열 치료 시장, 균주(DENV-2, DENV-3, DENV-1, DENV-4 및 기타), 유형(백신 및 아세트아미노펜), 심각도(경미한 ~ 중증 뎅기열 및 심각한 뎅기열), 투여 경로(비경구 및 경구), 구매 방식(처방 및 일반 의약품(OTC)), 성별(남성 및 여성), 연령(성인, 소아 및 노인), 최종 사용자(병원, 전문 병원, 재택 의료 및 기타), 유통 채널(소매 약국, 병원 약국 및 온라인 약국) - 업계 동향 및 2031년까지의 예측.
뎅기열 치료 시장 분석 및 규모
글로벌 뎅기열 치료 시장 성장을 담당하는 원동력은 의료 및 제약 산업에서 뎅기열 치료의 적용이 증가하고, 백신 출시가 지속적으로 증가하고, 의료 전문가와 공중 보건 당국이 사용할 수 있는 도구의 무기고가 확대되고 있기 때문입니다. 그러나 시장에 대한 상당한 제약은 뎅기열 치료와 관련된 부작용입니다.
Data Bridge Market Research에 따르면 글로벌 뎅기열 치료 시장은 2023년 8억 7,854만 달러에서 2031년 21억 2,143만 달러로 성장할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 11.6%일 것으로 예상됩니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2024년부터 2031년까지 |
|
기준 연도 |
2023 |
|
역사적 연도 |
2022 (2016-2021년까지 사용자 정의 가능) |
|
양적 단위 |
수익 (단위: USD 백만) |
|
다루는 세그먼트 |
균주(DENV-2, DENV-3, DENV-1, DENV-4 및 기타), 유형( 백신 및 아세트아미노펜), 심각도(경미한 ~ 중증 뎅기열 및 심각한 뎅기열), 투여 경로(비경구 및 경구), 구매 방식(처방 및 일반의약품(OTC)), 성별(남성 및 여성), 연령(성인, 소아 및 노인), 최종 사용자(병원, 전문 병원, 가정 의료 및 기타), 유통 채널(소매 약국, 병원 약국 및 온라인 약국) |
|
국가가 포함됩니다 |
미국, 캐나다, 멕시코, 독일, 영국, 이탈리아, 프랑스, 스페인, 러시아, 스위스, 터키, 벨기에, 네덜란드, 유럽 기타 지역, 일본, 중국, 한국, 인도, 싱가포르, 태국, 인도네시아, 말레이시아, 필리핀, 호주, 아시아 태평양 기타 지역, 브라질, 아르헨티나, 남미 기타 지역, 남아프리카, 이집트, 사우디 아라비아, UAE, 이스라엘, 중동 및 아프리카 기타 지역 |
|
시장 참여자 포함 |
Sanofi, Takeda Pharmaceutical Company Limited, Viatris Inc., Johnson & Johnson Services, Inc., GSK plc., Perrigo Company PLC, Baxter, Fresenius Kabi USA, Pfizer, Hikma Pharmaceuticals Plc, SUN PHARMACEUTICAL INDUSTRIES LTD, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma 등 |
시장 정의
뎅기열은 모기에 의해 전파되는 바이러스성 질병으로 최근 몇 년 동안 WHO의 모든 지역에서 빠르게 확산되었습니다. 뎅기열 바이러스는 주로 Aedes aegypti 속의 암컷 모기에 의해 전파되고, 덜한 정도로 Aedes albopictus에 의해 전파됩니다. 이러한 매개 모기에 의해 전파되는 질병에는 치쿤구냐, 황열병 및 지카 바이러스가 있습니다. 뎅기열은 열대 지역에서 만연하며, 강수량, 기온, 상대 습도 및 지역적 위험 변동성을 지닌 계획되지 않은 급속한 도시화로 인해 유발됩니다.
글로벌 뎅기열 치료 시장 역학
이 섹션에서는 시장 동인, 이점, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전자
- 뎅기열 발병률 증가로 효과적인 치료에 대한 수요 증가
뎅기열 발병률의 세계적 증가는 뎅기열 치료 시장의 중요한 원동력입니다. 뎅기열 바이러스에 의해 발생하고 이집트모기에 의해 전파되는 뎅기열은 전 세계적으로, 특히 열대 및 아열대 지역에서 사례가 극적으로 증가했습니다. 이러한 급증은 도시화, 기후 변화, 여행 증가와 같은 요인에 기인하며, 이는 바이러스와 모기 매개체의 확산을 촉진합니다. 영향을 받는 개인의 수가 증가함에 따라 효과적인 치료법과 예방 조치에 대한 수요가 증가합니다. 이로 인해 항바이러스 약물, 백신 및 지지 치료 옵션의 연구 개발에 대한 투자가 증가했습니다. 제약 회사와 연구 기관은 이 만연한 질병에 맞서기 위한 백신과 혁신적인 치료법을 개발하기 위한 노력을 강화하고 있습니다. 심각한 건강 합병증과 경제적 영향의 가능성과 더불어 높은 발병률은 뎅기열의 광범위하고 재발하는 위협을 완화하기 위해 뎅기열 치료 시장에 대한 투자와 발전을 촉진하고 있습니다.
- 뎅기열 백신 출시의 급증
뎅기열 백신 출시의 증가는 모기가 매개하는 이 질병과의 싸움에서 중요한 요인으로 지적됩니다. 뎅기열의 세계적 부담에 대한 인식이 높아지고 효과적인 예방 전략에 대한 절실한 필요성이 커지면서 제약 회사는 백신을 개발하고 출시하기 위한 노력을 강화하고 있습니다. 백신 출시의 급증은 의료 전문가와 공중 보건 당국이 사용할 수 있는 도구의 무기고를 확장함에 따라 시장 성장을 위한 중요한 원동력이 됩니다. 더 많은 백신이 시장에 출시됨에 따라 경쟁이 치열해져 혁신과 효능과 안전성을 강화하는 것을 목표로 하는 개선된 제형으로 이어집니다. 그 결과, 뎅기열 백신 시장은 강력한 성장을 목격하고 있으며, 향후 몇 년 동안 주요 업체의 시장 점유율과 수익이 지속적으로 확대될 것으로 예상됩니다.
기회
- 뎅기열 치료를 위한 파이프라인 백신 수 증가
뎅기열 치료를 위한 파이프라인 백신의 증가는 시장 성장에 대한 상당한 기회를 강화할 수 있습니다. 개발 중인 여러 후보가 있으므로 다양한 인구 통계 및 지리적 지역에서 효능, 안전성 및 적용 범위가 개선될 가능성이 있습니다. 이러한 측면은 개발자 간의 건전한 경쟁을 장려하여 혁신을 촉진하고 보다 비용 효율적인 솔루션을 추진합니다. 뎅기열은 특히 열대 및 아열대 지역에서 전 세계적인 건강 문제로 남아 있기 때문에 더 많은 백신을 공급하면 증가하는 수요를 충족하는 데 도움이 될 수 있습니다. 뎅기열 백신의 확장된 파이프라인은 중요한 공중 보건 요구를 해결할 뿐만 아니라 향상된 제품 제공과 제약 제조업체에 대한 기회 증가를 통해 시장 성장에 대한 유망한 전망을 제공합니다.
제약/도전
- 농촌 지역에서는 의료 서비스를 제한적으로 이용할 수 있습니다
뎅기열 치료에서 의료 서비스에 대한 접근성이 제한되면 주로 환자 풀이 감소하고 시기적절한 진단 및 치료가 방해를 받아 시장에 상당한 과제가 발생합니다. 적시에 의료를 찾는 환자가 줄어들면 질병 부담이 증가하여 더 심각한 사례와 더 높은 의료비가 발생할 위험이 있습니다. 접근성이 제한되면 영향을 받는 지역의 의료 시스템과 자원에 대한 부담이 심화되어 뎅기열 치료의 가용성과 경제성에 영향을 미칠 수 있습니다. 이러한 농촌 지역에는 잘 갖춰진 의료 시설과 전문 서비스가 부족하여 주민들이 적시에 양질의 치료를 받기 어렵습니다. 험준한 지형과 의료 시설까지의 먼 거리는 특히 교통망이 부족한 경우 문제를 악화시킵니다. 전반적으로 의료 서비스 접근성에 대한 장벽을 해결하는 것은 뎅기열을 효과적으로 관리하고 이 부문에서 시장 성장을 유지하는 데 중요합니다. 뎅기열 치료와 관련된 안전 문제는 특히 미용 및 의료 분야에서 널리 사용되고 있다는 점에서 상당한 과제입니다. 뎅기열 치료는 일반적으로 안전한 것으로 간주되고 인체에 자연적으로 존재하지만 피부 필러 및 기타 치료에 사용되는 합성 또는 추출 형태로 인해 잠재적인 위험이 발생합니다. 부작용에는 알레르기 반응, 감염, 육아종 형성이 포함될 수 있으며, 특히 물질이 적절하게 정제되거나 투여되지 않은 경우 그렇습니다. 또한, 부적절한 주사 기술은 혈관 폐색과 같은 합병증으로 이어질 수 있으며, 이는 조직 괴사와 심각한 경우 실명을 일으킬 수 있습니다. 따라서 뎅기열 치료 제품의 안전을 보장하려면 엄격한 품질 관리, 철저한 임상 테스트, 자격을 갖춘 의료 제공자의 전문적인 관리가 필요합니다.
- 백신 승인 절차 지연
뎅기열 백신 승인 절차의 지연은 시장 성장에 상당한 제약을 가하며, 백신 개발자와 공중 보건 이니셔티브 모두에게 다면적인 과제를 안겨줍니다. 규제 장벽, 엄격한 효능 및 안전 요건, 복잡한 시험 프로토콜은 백신 개발에서 시장 출시까지 시간이 오래 걸리는 데 기여합니다. 이러한 지연은 백신의 적시 출시를 방해하여 공중 보건 결과에 영향을 미치고 질병 발병 기간을 연장합니다. 게다가 승인 기간이 길어지면 회사가 불확실성의 위험이 높아지고 수익성이 감소할 수 있으므로 백신 연구 개발에 대한 투자가 억제될 수 있습니다. 게다가 승인 절차가 길어지면 개발 주기가 길어져 투자 수익에 대한 재정적 위험과 불확실성이 증가하기 때문에 투자자의 신뢰가 훼손됩니다. 게다가 뎅기열 백신의 출시가 늦어지면 벡터 제어 및 증상 치료와 같은 전통적인 예방 조치에 대한 의존도가 높아지는데, 이는 질병에 대한 포괄적인 보호를 제공하지 못할 수 있습니다. 이는 의료 인프라의 부담을 늘려 의료 비용이 증가하고 풍토병이 만연한 지역의 자원에 부담을 줍니다.
최근 개발 사항
- 2024년 5월, 존슨앤존슨(JNJ)은 Numab therapeutics의 전액 자회사인 Yellow Jersey Therapeutics(YJT)를 약 12억 5천만 달러 규모의 현금 거래로 인수하기로 최종 합의했다고 밝혔습니다. 이 전략적 인수는 생물제약 분야에서 포트폴리오를 확장하여 JNJ의 성장 궤도를 강화할 준비가 되었습니다. JNJ는 YJT의 혁신적인 파이프라인과 전문성을 통합하여 새로운 치료법 개발 역량을 강화하고 궁극적으로 의료 산업의 리더로서의 입지를 강화하고자 합니다.
- 2023년 8월 FDA 기사에 따르면, Sanofi Pasteur, Inc.에서 제조한 4가 생백신인 DENGVAXIA는 뎅기 바이러스의 1, 2, 3, 4 혈청형으로 인한 뎅기열 질환 예방에 적응증이 있습니다. 6~16세의 개인에게 승인되었으며, 실험실에서 확인된 이전 뎅기열 감염이 있는 풍토병 지역에 거주하는 사람을 특별히 대상으로 합니다. 이 백신은 뎅기열과 싸우는 데 있어 상당한 진전을 나타내며, 바이러스의 여러 혈청형에 대한 표적 보호를 제공하여 취약 계층의 뎅기열 감염 발생률을 잠재적으로 줄일 수 있습니다.
- Takeda Pharmaceutical Company Limited의 기사에 따르면, 2024년 2월, 이 회사는 뎅기열 4가 백신(생, 약독화)인 QDENGA를 연간 최대 5,000만 회분 생산하기로 약속했으며, 이는 2030년까지 연간 1억 회분을 공급한다는 Takeda의 목표를 앞당기는 것입니다. 이 다중회분 바이알(MDV)은 2030년까지 풍토병 국가에서 국가 예방 접종 프로그램을 위한 정부 조달을 지원하도록 지정되어 뎅기열 백신에 대한 더 광범위한 접근성을 용이하게 하고 전 세계 질병 예방 노력에 기여합니다. 또한, Takeda가 개발한 TDV와 NIH/Butantan Institute가 개발한 LAV Delta 30의 두 가지 생 약독화 뎅기열 백신이 3단계 개발 중입니다.
- 2019년 7월, Hikma Pharmaceuticals Inc.와 Civica Rx는 미국 지역의 미래 제네릭 의약품 부족을 최소화하기 위한 장기 계약을 체결했습니다. 이를 통해 회사는 제네릭 의약품 판매를 확대하고 순수익과 판매를 증가시킬 고객 기반을 구축하는 데 도움이 될 것입니다.
- 2019년 11월, Perrigo Company plc는 "Quitting is Better" 치료 캠페인이 Best OTC Corporate Social Responsibility Campaign 부문에서 주목할 만한 국가 상을 수상했다고 발표했습니다. 이 회사는 Consumer Healthcare Products Association(CHPA) 회원인 업계 대표로 구성된 자원 봉사 심사위원단으로부터 혁신과 전략적 마케팅 부문에서 수상했습니다. 이를 통해 글로벌 지역에서 회사의 프로필이 높아질 것입니다.
글로벌 뎅기열 치료 시장 범위
글로벌 뎅기열 치료 시장은 균주, 유형, 심각도, 투여 경로, 구매 방식, 성별, 연령, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 적용 영역과 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
균주
- DENV-2
- DENV-3
- DENV-1
- DENV-4
- 기타
시장은 균주에 따라 DENV-2, DENV-3, DENV-1, DENV-4 및 기타로 구분됩니다.
유형
- 백신
- 아세트아미노펜
시장은 유형을 기준으로 백신과 아세트아미노펜으로 구분됩니다.
심각성
- 경미한 ~ 중간 정도의 뎅기열
- 심각한 뎅기열
심각도에 따라 시장은 경미하거나 중간 정도의 뎅기열과 심각한 뎅기열로 구분됩니다.
투여 경로
- 비경구적
- 경구
투여 경로를 기준으로 시장은 비경구적 투여와 경구적 투여로 구분됩니다.
구매 방식
- 처방
- 일반의약품(OTC)
구매 방식을 기준으로 시장은 처방약과 일반의약품(OTC)으로 구분됩니다.
성별
- 남성
- 여성
성별을 기준으로 시장은 남성과 여성으로 구분됩니다.
나이
- 성인
- 소아과
- 노인
연령을 기준으로 시장은 성인, 소아, 노인으로 구분됩니다.
최종 사용자
- 병원
- 전문 클리닉
- 홈 헬스케어
- 기타
최종 사용자를 기준으로 시장은 병원, 전문 클리닉, 가정 건강 관리 및 기타로 구분됩니다.
유통 채널
- 소매 약국
- 병원 약국
- 온라인 약국
유통 채널을 기준으로 시장은 소매 약국, 병원 약국, 온라인 약국으로 구분됩니다.
글로벌 뎅기열 치료 시장 지역 분석/통찰력
글로벌 뎅기열 치료 시장을 분석하고, 균주, 유형, 심각도, 투여 경로, 구매 방식, 성별, 연령, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
글로벌 뎅기열 치료 시장에서 다루는 국가 는 미국, 캐나다, 멕시코, 독일, 영국, 이탈리아, 프랑스, 스페인, 러시아, 스위스, 터키, 벨기에, 네덜란드, 기타 유럽 국가, 일본, 중국, 한국, 인도, 싱가포르, 태국, 인도네시아, 말레이시아, 필리핀, 호주, 기타 아시아 태평양 국가, 브라질, 아르헨티나, 기타 남미 국가, 남아프리카 공화국, 이집트, 사우디 아라비아, UAE, 이스라엘, 기타 중동 및 아프리카 국가입니다.
아시아 태평양 지역은 이 지역의 의료 보험 성장으로 인해 글로벌 뎅기열 치료 시장을 주도할 것으로 예상됩니다 . 인도는 국가에서 뎅기열 백신 출시의 물결이 증가함에 따라 아시아 태평양 뎅기열 치료 시장을 주도할 것으로 예상됩니다. 프랑스는 정부의 이니셔티브와 국가의 예방 접종 프로그램으로 인해 유럽 뎅기열 치료 시장을 주도할 것으로 예상됩니다 . 브라질은 국가에서 뎅기열 발병률이 증가함에 따라 남미 뎅기열 치료 시장을 주도할 것으로 예상됩니다 .
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 추세 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 글로벌 뎅기열 치료 시장 점유율 분석
글로벌 뎅기열 치료 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 회사의 강점과 약점, 제품 출시, 제품 승인, 적용 우세, 제품 유형 수명선 곡선입니다. 위에 제공된 데이터 포인트는 회사의 시장 집중과만 관련이 있습니다.
이 시장에서 활동하는 주요 기업으로는 Sanofi, Takeda Pharmaceutical Company Limited, Viatris Inc., Johnson & Johnson Services, Inc., GSK plc., Perrigo Company PLC, Baxter, Fresenius Kabi USA, Pfizer, Hikma Pharmaceuticals Plc, SUN PHARMACEUTICAL INDUSTRIES LTD, Teva Pharmaceuticals USA, Inc., Aurobindo Pharma 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL DENGUE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 GLOBAL DENGUE TREATMENT MARKET: REGULATIONS
5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT
6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES
6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
6.2 RESTRAINTS
6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES
6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE
6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE
6.3 OPPORTUNITIES
6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET
6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT
6.3.3 RISING R&D INVESTMENT AND ACTIVITIES
6.4 CHALLENGES
6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS
6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS
7 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS
7.1 OVERVIEW
7.2 DENV-2
7.3 DENV-3
7.4 DENV-1
7.5 DENV-4
7.6 OTHERS
8 GLOBAL DENGUE TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 VACCINES
8.2.1 DENGVAXIA (CYD-TDV)
8.2.2 QDENGA
8.3 ACETAMINOPHEN
8.3.1 PARENTERAL
8.3.2 ORAL
8.3.3 OTHER
9 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY
9.1 OVERVIEW
9.2 MILD TO MODERATE DENGUE
9.3 SEVERE DENGUE
10 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 PARENTERAL
10.2.1 SUB-CUTANEOUS
10.2.2 INTRAVENOUS
10.3 ORAL
10.3.1 TABLET
10.3.2 CAPSULES
10.3.3 OTHERS
11 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE
11.1 OVERVIEW
11.2 PRESCRIPTION
11.3 OVER-THE-COUNTER (OTC)
12 GLOBAL DENGUE TREATMENT MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 GLOBAL DENGUE TREATMENT MARKET, BY AGE
13.1 OVERVIEW
13.2 ADULT
13.3 PEDIATRIC
13.4 GERIATRIC
14 GLOBAL DENGUE TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL PHARMACIES
15.3 HOSPITAL PHARMACIES
15.4 ONLINE PHARMACIES
16 GLOBAL DENGUE TREATMENT MARKET, BY REGION
16.1 OVERVIEW
16.2 ASIA-PACIFIC
16.2.1 INDIA
16.2.2 CHINA
16.2.3 JAPAN
16.2.4 INDONESIA
16.2.5 MALAYSIA
16.2.6 THAILAND
16.2.7 AUSTRALIA
16.2.8 SOUTH KOREA
16.2.9 SINGAPORE
16.2.10 PHILIPPINES
16.2.11 REST OF ASIA-PACIFIC
16.3 SOUTH AMERICA
16.3.1 BRAZIL
16.3.2 ARGENTINA
16.3.3 REST OF SOUTH AMERICA
16.4 NORTH AMERICA
16.4.1 MEXICO
16.4.2 U.S.
16.4.3 CANADA
16.5 EUROPE
16.5.1 FRANCE
16.5.2 GERMANY
16.5.3 SPAIN
16.5.4 U.K.
16.5.5 BELGIUM
16.5.6 ITALY
16.5.7 NETHERLANDS
16.5.8 RUSSIA
16.5.9 SWITZERLAND
16.5.10 TURKEY
16.5.11 REST OF EUROPE
16.6 MIDDLE EAST AND AFRICA
16.6.1 EGYPT
16.6.2 SAUDI ARABIA
16.6.3 SOUTH AFRICA
16.6.4 U.A.E
16.6.5 ISRAEL
16.6.6 REST OF MIDDLE EAST AND AFRICA
17 GLOBAL DENGUE TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 SANOFI
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 JOHNSON & JOHNSON SERVICES, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 GSK PLC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 AUROBINDO PHARMA
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.7 BAXTER
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.8 FRESENIUS KABI USA
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 HIKMA PHARMACEUTICALS
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 PERRIGO COMPANY PLC
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 PFIZER INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 TEVA PHARMACEUTICALS USA, INC.
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
표 목록
TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS
TABLE 3 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 4 GLOBAL DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 GLOBAL DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 13 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 14 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 17 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 18 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 19 GLOBAL MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 GLOBAL SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 22 GLOBAL PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 GLOBAL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 GLOBAL ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 GLOBAL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 27 GLOBAL PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 28 GLOBAL OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 GLOBAL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 30 GLOBAL MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 GLOBAL FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 GLOBAL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 33 GLOBAL ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 GLOBAL PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 35 GLOBAL GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 GLOBAL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 37 GLOBAL HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 GLOBAL SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 GLOBAL HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 GLOBAL OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 GLOBAL RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 GLOBAL HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 GLOBAL ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 GLOBAL DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 46 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 47 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 48 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 51 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 52 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 54 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 55 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 56 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 57 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 60 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 61 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 62 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 63 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 64 INDIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 65 INDIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 68 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 69 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 71 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 72 INDIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 73 INDIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 74 INDIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 INDIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 INDIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 77 INDIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 78 INDIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 79 INDIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 INDIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 81 CHINA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 82 CHINA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 85 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 86 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 88 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 89 CHINA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 90 CHINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 91 CHINA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 CHINA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 CHINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 94 CHINA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 95 CHINA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 96 CHINA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 97 CHINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 98 JAPAN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 99 JAPAN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 102 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 103 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 105 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 106 JAPAN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 107 JAPAN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 108 JAPAN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 JAPAN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 JAPAN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 111 JAPAN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 112 JAPAN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 113 JAPAN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 114 JAPAN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 115 INDONESIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 116 INDONESIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 118 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 119 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 120 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 121 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 122 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 123 INDONESIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 124 INDONESIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 125 INDONESIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 INDONESIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 INDONESIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 128 INDONESIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 129 INDONESIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 130 INDONESIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 131 INDONESIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 132 MALAYSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 133 MALAYSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 136 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 137 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 139 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 140 MALAYSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 141 MALAYSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 142 MALAYSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 MALAYSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 MALAYSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 145 MALAYSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 146 MALAYSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 147 MALAYSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 148 MALAYSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 149 THAILAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 150 THAILAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 151 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 152 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 153 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 154 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 156 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 157 THAILAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 158 THAILAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 159 THAILAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 THAILAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 THAILAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 162 THAILAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 163 THAILAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 164 THAILAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 165 THAILAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 166 AUSTRALIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 167 AUSTRALIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 170 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 171 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 173 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 174 AUSTRALIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 175 AUSTRALIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 176 AUSTRALIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 177 AUSTRALIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 AUSTRALIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 179 AUSTRALIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 180 AUSTRALIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 181 AUSTRALIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 182 AUSTRALIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 SOUTH KOREA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 184 SOUTH KOREA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 187 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 188 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 190 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 191 SOUTH KOREA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 192 SOUTH KOREA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 193 SOUTH KOREA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 SOUTH KOREA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 195 SOUTH KOREA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 196 SOUTH KOREA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 197 SOUTH KOREA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 198 SOUTH KOREA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 199 SOUTH KOREA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 SINGAPORE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 201 SINGAPORE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 204 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 205 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 207 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 208 SINGAPORE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 209 SINGAPORE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 210 SINGAPORE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 211 SINGAPORE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 212 SINGAPORE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 213 SINGAPORE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 214 SINGAPORE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 215 SINGAPORE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 216 SINGAPORE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 217 PHILIPPINES DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 218 PHILIPPINES DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 220 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 221 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 222 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 224 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 225 PHILIPPINES DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 226 PHILIPPINES DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 227 PHILIPPINES PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 PHILIPPINES ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 PHILIPPINES DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 230 PHILIPPINES DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 231 PHILIPPINES DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 232 PHILIPPINES DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 233 PHILIPPINES DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 234 REST OF ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 235 SOUTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 236 SOUTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 237 SOUTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 239 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 240 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 241 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 242 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 243 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 244 SOUTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 245 SOUTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 246 SOUTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 247 SOUTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 SOUTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 249 SOUTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 250 SOUTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 251 SOUTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 252 SOUTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 253 BRAZIL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 254 BRAZIL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 257 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 258 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 260 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 261 BRAZIL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 262 BRAZIL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 263 BRAZIL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 264 BRAZIL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 265 BRAZIL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 266 BRAZIL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 267 BRAZIL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 268 BRAZIL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 BRAZIL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 ARGENTINA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 271 ARGENTINA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 274 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 275 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 276 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 277 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 278 ARGENTINA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 279 ARGENTINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 280 ARGENTINA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 ARGENTINA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 282 ARGENTINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 283 ARGENTINA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 284 ARGENTINA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 285 ARGENTINA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 286 ARGENTINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 287 REST OF SOUTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 288 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 289 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 290 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 292 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 293 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 294 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 295 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 296 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 297 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 298 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 299 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 300 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 301 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 302 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 303 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 304 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 305 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 306 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 307 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 308 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 309 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 310 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 311 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 312 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 313 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 314 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 315 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 316 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 317 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 318 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 319 MEXICO DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 320 MEXICO DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 321 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 322 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 323 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 324 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 325 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 326 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 327 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 328 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 329 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 330 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 331 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 332 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 333 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 334 U.S. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 335 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 336 U.S. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 337 U.S. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 338 U.S. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 339 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 340 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 341 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 342 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 343 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 344 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 345 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 346 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 347 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 348 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 349 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 350 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 351 CANADA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 352 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 353 CANADA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 354 CANADA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 355 CANADA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 356 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 357 EUROPE DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 358 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 359 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 360 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 361 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 362 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 363 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 364 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 365 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 366 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 367 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 368 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 369 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 370 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 371 EUROPE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 372 EUROPE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 373 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 374 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 375 FRANCE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 376 FRANCE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 377 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 378 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 379 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 380 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 381 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 382 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 383 FRANCE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 384 FRANCE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 385 FRANCE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 386 FRANCE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 387 FRANCE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 388 FRANCE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 389 FRANCE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 390 FRANCE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 391 FRANCE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 392 GERMANY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 393 GERMANY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 394 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 395 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 396 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 397 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 398 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 399 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 400 GERMANY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 401 GERMANY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 402 GERMANY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 403 GERMANY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 404 GERMANY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 405 GERMANY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 406 GERMANY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 407 GERMANY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 408 GERMANY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 409 SPAIN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 410 SPAIN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 411 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 412 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 413 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 414 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 415 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 416 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 417 SPAIN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 418 SPAIN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 419 SPAIN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 420 SPAIN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 421 SPAIN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 422 SPAIN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 423 SPAIN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 424 SPAIN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 425 SPAIN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 426 U.K. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 427 U.K. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 428 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 429 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 430 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 431 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 432 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 433 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 434 U.K. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 435 U.K. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 436 U.K. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 437 U.K. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 438 U.K. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 439 U.K. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 440 U.K. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 441 U.K. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 442 U.K. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 443 BELGIUM DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 444 BELGIUM DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 445 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 446 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 447 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 448 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 449 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 450 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 451 BELGIUM DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 452 BELGIUM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 453 BELGIUM PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 454 BELGIUM ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 455 BELGIUM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 456 BELGIUM DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 457 BELGIUM DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 458 BELGIUM DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 459 BELGIUM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 460 ITALY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 461 ITALY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 462 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 463 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 464 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 465 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 466 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 467 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 468 ITALY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 469 ITALY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 470 ITALY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 471 ITALY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 472 ITALY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 473 ITALY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 474 ITALY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 475 ITALY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 476 ITALY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 477 NETHERLANDS DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 478 NETHERLANDS DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 479 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 480 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 481 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 482 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 483 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 484 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 485 NETHERLANDS DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 486 NETHERLANDS DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 487 NETHERLANDS PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 488 NETHERLANDS ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 489 NETHERLANDS DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 490 NETHERLANDS DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 491 NETHERLANDS DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 492 NETHERLANDS DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 493 NETHERLANDS DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 494 RUSSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 495 RUSSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 496 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 497 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 498 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 499 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 500 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 501 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 502 RUSSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 503 RUSSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 504 RUSSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 505 RUSSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 506 RUSSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 507 RUSSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 508 RUSSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 509 RUSSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 510 RUSSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 511 SWITZERLAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 512 SWITZERLAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 513 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 514 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 515 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 516 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 517 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 518 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 519 SWITZERLAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 520 SWITZERLAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 521 SWITZERLAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 522 SWITZERLAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 523 SWITZERLAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 524 SWITZERLAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 525 SWITZERLAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 526 SWITZERLAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 527 SWITZERLAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 528 TURKEY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 529 TURKEY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 530 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 531 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 532 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 533 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 534 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 535 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 536 TURKEY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 537 TURKEY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 538 TURKEY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 539 TURKEY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 540 TURKEY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 541 TURKEY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 542 TURKEY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 543 TURKEY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 544 TURKEY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 545 REST OF EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 546 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 547 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 548 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 549 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 550 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 551 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 552 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 553 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 554 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 555 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 556 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 557 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 558 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 559 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 560 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 561 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 562 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 563 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 564 EGYPT DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 565 EGYPT DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 566 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 567 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 568 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 569 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 570 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 571 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 572 EGYPT DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 573 EGYPT DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 574 EGYPT PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 575 EGYPT ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 576 EGYPT DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 577 EGYPT DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 578 EGYPT DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 579 EGYPT DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 580 EGYPT DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 581 SAUDI ARABIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 582 SAUDI ARABIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 583 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 584 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 585 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 586 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 587 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 588 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 589 SAUDI ARABIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 590 SAUDI ARABIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 591 SAUDI ARABIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 592 SAUDI ARABIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 593 SAUDI ARABIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 594 SAUDI ARABIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 595 SAUDI ARABIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 596 SAUDI ARABIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 597 SAUDI ARABIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 598 SOUTH AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 599 SOUTH AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 600 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 601 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 602 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 603 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 604 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 605 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 606 SOUTH AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 607 SOUTH AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 608 SOUTH AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 609 SOUTH AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 610 SOUTH AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 611 SOUTH AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 612 SOUTH AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 613 SOUTH AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 614 SOUTH AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 615 U.A.E DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 616 U.A.E DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 617 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 618 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 619 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 620 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 621 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 622 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 623 U.A.E DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 624 U.A.E DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 625 U.A.E PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 626 U.A.E ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 627 U.A.E DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 628 U.A.E DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 629 U.A.E DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 630 U.A.E DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 631 U.A.E DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 632 ISRAEL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 633 ISRAEL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 634 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 635 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 636 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 637 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 638 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 639 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 640 ISRAEL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 641 ISRAEL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 642 ISRAEL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 643 ISRAEL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 644 ISRAEL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 645 ISRAEL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 646 ISRAEL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 647 ISRAEL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 648 ISRAEL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 649 REST OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
그림 목록
FIGURE 1 GLOBAL DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL DENGUE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL DENGUE TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE GLOBAL DENGUE TREATMENT MARKET FROM 2024 TO 2031
FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DENGUE TREATMENT MARKET IN 2024 AND 2031
FIGURE 13 ASIA-PACIFIC IS EXPECTED TO DOMINATE THE GLOBAL DENGUE TREATMENT MARKET AND EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR GLOBAL DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL DENGUE TREATMENT MARKET
FIGURE 16 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA
FIGURE 17 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, 2023
FIGURE 18 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)
FIGURE 19 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)
FIGURE 20 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 21 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, 2023
FIGURE 22 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 23 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 24 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, 2023
FIGURE 26 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)
FIGURE 27 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)
FIGURE 28 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 29 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 30 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 31 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 32 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 33 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023
FIGURE 34 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
FIGURE 35 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)
FIGURE 36 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 37 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, 2023
FIGURE 38 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 39 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 40 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 41 GLOBAL DENGUE TREATMENT MARKET: BY AGE, 2023
FIGURE 42 GLOBAL DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)
FIGURE 43 GLOBAL DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)
FIGURE 44 GLOBAL DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 45 GLOBAL DENGUE TREATMENT MARKET: BY END USER, 2023
FIGURE 46 GLOBAL DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 47 GLOBAL DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)
FIGURE 48 GLOBAL DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 49 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 50 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 51 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 52 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 GLOBAL DENGUE TREATMENT MARKET: SNAPSHOT (2023)
FIGURE 54 GLOBAL DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 55 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 56 EUROPE DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 57 AISA-PACIFIC DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
